From: Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin
IBC
Non-IBC
n (%)
p value
Basal cases (ER-, ERBB2-)
24 (33.8%)
58 (15.93%)
<0.001
ERBB2-overexpressing cases
24 (33.33%)
51 (14.49%)
Luminal cases (ER+, PR+)
22 (29.33%)
221 (58.93%)